- Long Term Safety
was not measurable in the circulation, and no systemic effects were
seen with bolus doses of Lyumjev up to 50 units in phase 1b
has been approved to treat PAH for approximately 15 years and
the safety profile is established.5
the treatment of PAH, treprostinil is used at initial doses of
1.25 ng/kg/min as a continuous infusion and achieves an average
steady state concentration that is at least 200-fold higher than the
levels in patients treated with Lyumjev.4,5
the formulation of Lyumjev, microdoses of treprostinil are used
as an excipient to increase blood flow at the site of injection
through localized vasodilation.1-3
commercial formulation of Lyumjev contains 10 ng of treprostinil per
unit of insulin lispro in a 100-unit/mL formulation.4
Leohr J, Pratt E, Heilmann C, et al. Treprostinil causes local
vasodilation is well tolerated, and results in faster absorption of
insulin lispro [abstract]. Diabetologia. 2017;60(suppl
Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro
formulation containing citrate and treprostinil demonstrates faster
absorption and onset of insulin action in healthy subjects
[abstract]. Diabetes. 2017;66(suppl 1):A253.
Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local
vasodilation, is well tolerated, and results in faster absorption of
insulin lispro [abstract]. Diabetes. 2017;66(suppl 1):A253.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Remodulin [package insert]. Research Triangle Park, NC: United
Therapeutics Corp.; 2018.
= pulmonary arterial hypertension
= Remodulin® (treprostinil) injection
= ultra rapid lispro
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.